Stocktoria
Nuvectis Pharma, Inc. NVCT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-02-04
Nuvectis Pharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $18.2M | $12.9M | $15.4M | $13.2M | $9.5M |
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M | -$12.9M |
| Net income | -$26.4M | -$19.0M | -$22.3M | -$19.1M | -$12.9M |
| EPS (diluted) | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 |
| Operating cash flow | -$16.0M | -$12.2M | -$16.0M | -$13.6M | -$9.5M |
| Cash & equivalents | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Shareholders' equity | $18.4M | $9.7M | $12.2M | $14.2M | -$11.0M |
Source: SEC EDGAR filings · CIK 0001875558 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.